

# A systematic review of genetic risk factors for neuropathic pain in adults with diabetes mellitus

Harry L. Hébert\*, Imran K. Jallaldeen, Fatima Farida, Bhushan Thakkar, Abirami Veluchamy, Lesley A. Colvin, Blair H. Smith

Chronic Pain Research Group, Division of Population Health and Genomics, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

\*Email: [h.hebert@dundee.ac.uk](mailto:h.hebert@dundee.ac.uk)

Poster Number: TU196

## Introduction

- Neuropathic pain (NP) is a debilitating condition affecting 7-10% of the general population and 25% of people with diabetes mellitus (DM).
- There is large interindividual variation in the onset of NP in people with DM.
- Our previous systematic review identified genetic risk factors for NP, but no studies have attempted to collate the data specifically in people with DM.
- Identifying genetic risk factors will reveal the mechanisms that contribute to its development and help inform prevention and treatment.

## Aims

- To conduct a systematic review to identify all published studies investigating genetic risk factors for chronic NP in adults with DM.
- To summarise the genetic risk factors for chronic NP in DM through narrative synthesis.

## Methods

### Design

- PROSPERO ID: CRD42022335554

### Databases

- Cochrane, Embase (Ovid), PubMed, Scopus and Web of Science

### Screening

- Title/abstract and full-text screening was conducted by two reviewers.

### Risk of bias

- Studies assessed by two reviewers using Q-GENIE.

Table 1 – Study criteria using the PICO framework

Parameter	Inclusions	Exclusions
Population	- Participants ≥ 18 years - Diabetes (any type)	- Participants < 18 years - Animal studies - Non-diabetics
Exposure	- Genetic factors (risk variant)	n/a
Control	- Genetic factors (reference variant)	n/a
Outcomes	- Neuropathic pain (presence/absence) - Duration ≥ 3 months	n/a
Time Scale	- Up to 17 <sup>th</sup> June 2023	n/a
Study Type	- Candidate gene association study - Genome-wide association study - Targeted/whole genome Sequencing	- Case study or series - Conference abstracts - Studies without access to full-text - Studies not in English




Figure 1 – PRISMA flow chart

## Results

Table 2 – Study characteristics

Study	Type	NP Outcome	Sample size (cases/controls)	Quality Rating*
Almomani R <i>et al.</i> 2023	Targeted sequencing	pDN	237/309	Moderate
Alsalam M <i>et al.</i> 2019	Targeted sequencing	pDN	230/317	Moderate
Blesneac I <i>et al.</i> 2018	Targeted sequencing	pDN	111/78	Moderate
Sleczkowska M <i>et al.</i> 2022	Targeted sequencing	pDN	222/304	Moderate
Veluchamy A <i>et al.</i> 2021	GWAS	General NP	383/420	Good
Wadhawan S <i>et al.</i> 2017	Targeted sequencing	pDN	138/41	Moderate

GWAS, genome-wide association study; NP, neuropathic pain; pDN, painful diabetic neuropathy  
\*Based on Q-GENIE

Table 3 – Rare potentially pathogenic variants identified in people with DM with and without neuropathic pain

Transporter Pathway	Gene	Chromosome	Number of variants (NP/no NP)	Number of studies
Sodium Channel	SCN3A	2	3/3	1
	SCN7A	2	6/3	1
	SCN8A	12	2/2	1
	SCN9A	2	21/9	3
	SCN10A	3	11/17	2
	SCN11A	3	4/5	1
	SCN1B	19	1/1	1
	SCN2B	11	2/2	2
Chloride channel	ANO1	11	0/1	1
	ANO3	11	3/0	1
Potassium channel	KCNK18	10	2/2	1
	KCNQ3	8	0/1	1
	HCN1	5	1/0	1
Cation channel	TRPA1	8	3/2	1
	TRPM8	2	3/1	1
	TRPV1	17	0/3	1
	TRPV4	12	1/3	1

DM, diabetes mellitus; NP, neuropathic pain

## Discussion

### Conclusions

- The findings demonstrate a potential role of genetic factors in the onset of NP in people with DM.
- However, further high-powered studies are needed with consistent case definition and statistical analysis, particularly genome-wide association studies.
- Non-genetic factors are also being investigated in a separate systematic review.

### Relevance for Patient Care

- Elucidating the genetics underpinning NP in DM may lead to the development of new therapies and enable patient stratification that will inform both prevention and treatment.

## References

- Almomani R *et al.* Genetic profiling of sodium channels in diabetic painful and painless and idiopathic painful and painless neuropathies. *Int J Mol Sci* 2023, 24(9):8278.
- Alsalam M *et al.* A gain-of-function sodium channel  $\beta$ 2-subunit mutation in painful diabetic neuropathy. *Mol Pain* 2019, 15:1744806919849802.
- Blesneac I *et al.* Rare  $Na_v1.7$  variants associated with painful diabetic peripheral neuropathy. *Pain* 2018, 159(3):469-480.
- Sleczkowska M *et al.* Peripheral ion channel gene screening in painful-and painless-diabetic neuropathy. *Int J Mol Sci* 2022, 23(13):7190.
- Veluchamy A *et al.* Association of genetic variant at chromosome 12q23.1 with neuropathic pain susceptibility. *JAMA Netw Open* 2021, 4(12):e2136560.
- Wadhawan S *et al.*  $Na_v$  channel variants in patients with painful and nonpainful peripheral neuropathy. *Neurol Genet* 2017, 3(6):e207.